SCHEMBL15840450

SCHEMBL15840450

CC(C)CCC(=O)N1CCN(c2ccc(Cl)cc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.61
MEN1 O00255 4/20 0.61
MAPT P10636 3/20 0.61
HTR7 P34969 3/20 0.60
HTR1A P08908 2/20 0.60
AKR1C3 P42330 1/20 0.59
HDAC1 Q13547 1/20 0.59
POLB P06746 1/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
ADAMTS5 Q9UNA0 2/20 0.57
LMNA P02545 2/20 0.57
ALDH1A1 P00352 1/20 0.57
HTT P42858 1/20 0.57
NPC1 O15118 1/20 0.56
GAA P10253 1/20 0.56
MAPK1 P28482 1/20 0.56
RAB9A P51151 1/20 0.56
CNR1 P21554 1/20 0.56
ME2 P23368 1/20 0.56
ME1 P48163 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15840437 0.86 GFER (0.61) KMT2AMEN1MAPTPOLBSMN1; SMN2
SCHEMBL7511899 0.85 KMT2A (0.58) KMT2AMEN1MAPTHTR7HTR1A
SCHEMBL15840436 0.85 MAPT (0.69) KMT2AMEN1MAPTHTR7HTR1A
SCHEMBL25443710 0.83 ALDH1A1 (0.48) KMT2AMEN1MAPTHTR7HTR1A
SCHEMBL9987526 0.82 KMT2A (0.68) KMT2AMEN1MAPTHTR7HTR1A
SCHEMBL12419699 0.80 AKR1C3 (0.68) KMT2AMEN1MAPTHTR7HTR1A
SCHEMBL2867356 0.79 AKR1C3 (0.69) KMT2AMEN1MAPTHTR7HTR1A
SCHEMBL30862677 0.78 MAPT (0.58) KMT2AMEN1MAPTPOLBSMN1; SMN2
SCHEMBL17208422 0.78 KMT2A (0.59) KMT2AMEN1MAPTHTR7HTR1A
SCHEMBL7561191 0.77 AKR1C3 (0.68) KMT2AMEN1MAPTHTR7HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9957249-B2 Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against Mycobacteria UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) 2018-05-01 US disclosed
US-9957249-B2 Saturated nitrogen and N-acylated heterocycles potentiating the activity of an active antibiotic against Mycobacteria UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) 2018-05-01 US disclosed
US-20150307471-A1 Saturated Nitrogen and N-Acylated Heterocycles Potentiating the Activity of an Active Antibiotic against Mycobacteria UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) 2015-10-29 US disclosed
US-20150307471-A1 Saturated Nitrogen and N-Acylated Heterocycles Potentiating the Activity of an Active Antibiotic against Mycobacteria UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) 2015-10-29 US disclosed
WO-2014096378-A1 SATURATED NITROGEN AND N-ACYLATED HETEROCYCLES POTENTIATING THE ACTIVITY OF AN ACTIVE ANTIBIOTIC AGAINST MYCOBACTERIA UNIVERSITE DE DROIT ET DE LA SANTE DE LILLE 2 (FR) 2014-06-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150307471-A1 Saturated Nitrogen and N-Acylated Heterocycles Potentiating the Activity of an Active Antibiotic against Mycobacteria NAT1, NAA15, FNTB KMT2A 2635/4885MEN1 461/4885MAPT 3715/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.